Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
about
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trialTreating refractory leukemias in childhood, role of clofarabineBeyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute LeukemiaPrognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology GroupA balanced iterative random forest for gene selection from microarray dataOutcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia.Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001.Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.Identification of hepatic niche harboring human acute lymphoblastic leukemic cells via the SDF-1/CXCR4 axis.Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemiaCD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells.Health-related quality of life in long-term survivors of relapsed childhood acute lymphoblastic leukemiaPediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation.Sulforaphane induces cell cycle arrest and apoptosis in acute lymphoblastic leukemia cellsA phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhoT-cell-replete haploidentical stem cell transplantation is highly efficacious for relapsed and refractory childhood acute leukaemiaRas pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibitionHigh-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant?Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia.Survival of Mexican Children with Acute Lymphoblastic Leukaemia under Treatment with the Protocol from the Dana-Farber Cancer Institute 00-01Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemiaMethotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology GroupTargeting paediatric acute lymphoblastic leukaemia: novel therapies currently in developmentOutcomes after induction failure in childhood acute lymphoblastic leukemia.Meta-analysis of gene expression in relapsed childhood B-acute lymphoblastic leukemiaTransplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research.Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome.Advances in the Biology of Acute Lymphoblastic Leukemia-From Genomics to the ClinicClinical potential of targeting Bruton's tyrosine kinase.Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemiaInitial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia.Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia.Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions.Treatment of relapsed precursor-B acute lymphoblastic leukemia with intensive chemotherapy: POG (Pediatric Oncology Group) study 9411 (SIMAL 9).Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.
P2860
Q24621523-DA9CA547-9248-4D47-A071-396F8E864257Q24647279-80F10A04-C406-47BD-8DD5-C90849B611F5Q26781328-BB9AAC8C-C3D0-4514-86F8-46658EAE386FQ27851831-62D5E427-90F9-4DDC-BD9F-D4C485FD3649Q30417943-F65BC476-A169-4CBA-A9F1-D48522847A6DQ30663691-564B4582-C311-40AB-8CA5-A4532546B021Q33628794-4E1CE79C-5E3C-4194-9CA8-C253B9602D6FQ33631405-7F381014-01E9-421D-9E9E-7BF8CDED4B06Q33647130-F0FBF117-2F8F-45F1-92C1-2C4093BA0271Q33711119-11B1EFE0-2293-4AD7-87B0-9DE6EDF3A2CAQ34070556-47D48FA9-4E85-4BD5-B87A-B95674487F8FQ34131813-10091C89-DE2D-4E68-93D4-93D5C2629B22Q34154532-0572C152-38BB-4DE6-9615-F618BDFD985AQ34291473-E83CE54C-EC86-4086-BFFF-C4C5AD23B29BQ34490429-CCD96D89-6BEE-40E2-BF52-0708861BACA6Q34516308-FA0B96AB-78FC-4162-9D4C-C7BA3CDF005DQ34547528-FF1039C6-29A7-4AA6-B484-F4FB0E8161E7Q34557915-6E0DCB2D-FE94-432B-BBD3-75DC1BD87F7CQ34580110-D0E1A024-3698-4953-8170-E7AA1E2CEC73Q34645259-3C673790-9AEF-434D-AD3B-BB3711829529Q35183874-A1F34859-4138-4180-A491-BB68D162186AQ35437903-00115E53-EC5C-4529-A0BD-240689DB70E2Q35643010-8BEC6020-7B0C-4654-9E13-28285B42B37DQ35684384-B0F891B5-072A-4B73-B3FF-5D57ED21E828Q35953635-65C97EE1-6B1E-4ECC-85BF-AB6B8A18A8FAQ35967452-509DB057-D049-4436-A534-A4068C4FE00AQ36029619-17BA7E9B-51B2-4872-A2C5-5E661C6E40A1Q36276060-19D7F537-AC97-498A-A425-B7F6D186A6F8Q36302281-B5724FAB-A5E9-4556-ABCD-6244D1FA200EQ36420748-D9439FCD-9B39-49D0-B9B8-5E5F8DDA0AA0Q36752634-DEAF1F07-5EFC-4C53-9712-8322B7A7B489Q37094690-DC206E5A-491B-4E7A-8D4D-C5E2D2BEAAB3Q37124911-0056F7D8-76AF-4B0E-B65F-297492975CA9Q37126126-ECD054E9-903A-44CE-AD8F-50F728FDC4DAQ37268926-F90D11B3-B9D6-43CF-B38B-D08E77E51181Q37296134-8E1ED3AC-0337-4DDB-AA5C-5E63AA72603BQ37351577-6BDAFD60-45F8-4518-98B6-42F100A87F26Q37401075-5A48ED7C-BDB8-4A1B-BBED-D085F8FC69B5Q37642540-68AAF7B4-7C76-4651-9BC3-D21B4D103A0CQ37677743-C094ED7E-EC4B-4659-A952-4F0C4CBD6590
P2860
Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Long-term outcome in children ...... in-Frankfurt-Münster Group 87.
@en
type
label
Long-term outcome in children ...... in-Frankfurt-Münster Group 87.
@en
prefLabel
Long-term outcome in children ...... in-Frankfurt-Münster Group 87.
@en
P2093
P50
P356
P1476
Long-term outcome in children ...... in-Frankfurt-Münster Group 87.
@en
P2093
Georg Mann
Gritta Janka-Schaub
Günter Henze
Hagen Graf Einsiedel
Karel Hählen
Reinhard Hartmann
Rüdiger Fengler
Ulrich Göbel
Wolf-Dieter Ludwig
P304
P356
10.1200/JCO.2005.01.1031
P407
P577
2005-11-01T00:00:00Z